FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806488008> ?p ?o ?g. }

• W2806488008 endingPage "672" @default.
• W2806488008 startingPage "661" @default.
• W2806488008 abstract "Chronic visual loss is a disabling feature in patients with multiple sclerosis (MS). It was recently shown that MD1003 (high-dose pharmaceutical-grade biotin or hdPB) may improve disability in patients with progressive MS.The aim of this study was to evaluate whether MD1003 improves vision compared with placebo in MS patients with chronic visual loss.The MS-ON was a 6-month, randomized, double-blind, placebo-controlled study with a 6-month open-label extension phase. Adult patients with MS-related chronic visual loss of at least one eye [visual acuity (VA) below 0.5 decimal chart] were randomized 2:1 to oral MD1003 300 mg/day or placebo. The selected eye had to show worsening of VA within the past 3 years following either acute optic neuritis (AON) or slowly progressive optic neuropathy (PON). The primary endpoint was the mean change from baseline to month 6 in VA measured in logarithm of the minimum angle of resolution (logMAR) at 100% contrast of the selected eye. Visually evoked potentials, visual field, retinal nerve fiber layer (RNFL) thickness, and health outcomes were also assessed.Ninety-three patients received MD1003 (n = 65) or placebo (n = 28). The study did not meet its primary endpoint, as the mean change in the primary endpoint was nonsignificantly larger (p = 0.66) with MD1003 (- 0.061 logMAR, + 3.1 letters) than with placebo (- 0.036 logMAR, + 1.8 letters). Pre-planned subgroup analyses showed that 100% contrast VA improved by a mean of + 2.8 letters (- 0.058 logMAR) with MD1003 and worsened by - 1.5 letters (+ 0.029 logMAR) with placebo (p = 0.45) in the subgroup of patients with PON. MD1003-treated patients also had nonsignificant improvement in logMAR at 5% contrast and in RNFL thickness and health outcome scores when compared with placebo-treated patients. There was no superiority of MD1003 vs placebo in patients with AON. The safety profile of MD1003 was similar to that of placebo.MD1003 did not significantly improve VA compared with placebo in patients with MS experiencing chronic visual loss. An interesting trend favoring MD1003 was observed in the subgroup of patients with PON. Treatment was overall well tolerated.EudraCT identifier 2013-002112-27. ClinicalTrials.gov Identifier: NCT02220244 FUNDING: MedDay Pharmaceuticals." @default.
• W2806488008 created "2018-06-13" @default.
• W2806488008 creator A5006513938 @default.
• W2806488008 creator A5006997286 @default.
• W2806488008 creator A5007098026 @default.
• W2806488008 creator A5009133924 @default.
• W2806488008 creator A5009282279 @default.
• W2806488008 creator A5011213325 @default.
• W2806488008 creator A5011728381 @default.
• W2806488008 creator A5011893848 @default.
• W2806488008 creator A5014816629 @default.
• W2806488008 creator A5020724517 @default.
• W2806488008 creator A5021292901 @default.
• W2806488008 creator A5022957204 @default.
• W2806488008 creator A5038662347 @default.
• W2806488008 creator A5044284630 @default.
• W2806488008 creator A5047268222 @default.
• W2806488008 creator A5054006135 @default.
• W2806488008 creator A5061783443 @default.
• W2806488008 creator A5064342215 @default.
• W2806488008 creator A5081885557 @default.
• W2806488008 creator A5082292870 @default.
• W2806488008 date "2018-05-28" @default.
• W2806488008 modified "2023-10-17" @default.
• W2806488008 title "MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study" @default.
• W2806488008 cites W1225123808 @default.
• W2806488008 cites W1968513811 @default.
• W2806488008 cites W1969041418 @default.
• W2806488008 cites W1972752407 @default.
• W2806488008 cites W1981679538 @default.
• W2806488008 cites W203209797 @default.
• W2806488008 cites W2036601077 @default.
• W2806488008 cites W2045464822 @default.
• W2806488008 cites W2045706760 @default.
• W2806488008 cites W2052016181 @default.
• W2806488008 cites W2059415178 @default.
• W2806488008 cites W2074734666 @default.
• W2806488008 cites W2084846759 @default.
• W2806488008 cites W2092500665 @default.
• W2806488008 cites W2100830657 @default.
• W2806488008 cites W2107345961 @default.
• W2806488008 cites W2115898509 @default.
• W2806488008 cites W2122545833 @default.
• W2806488008 cites W2123311421 @default.
• W2806488008 cites W2125442932 @default.
• W2806488008 cites W2142577589 @default.
• W2806488008 cites W2155102333 @default.
• W2806488008 cites W2223385692 @default.
• W2806488008 cites W2326826867 @default.
• W2806488008 cites W2326911230 @default.
• W2806488008 cites W2416021904 @default.
• W2806488008 cites W2510859603 @default.
• W2806488008 cites W2757836920 @default.
• W2806488008 cites W2786902975 @default.
• W2806488008 doi "https://doi.org/10.1007/s40263-018-0528-2" @default.
• W2806488008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6061426" @default.
• W2806488008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29808469" @default.
• W2806488008 hasPublicationYear "2018" @default.
• W2806488008 type Work @default.
• W2806488008 sameAs 2806488008 @default.
• W2806488008 citedByCount "23" @default.
• W2806488008 countsByYear W28064880082019 @default.
• W2806488008 countsByYear W28064880082020 @default.
• W2806488008 countsByYear W28064880082021 @default.
• W2806488008 countsByYear W28064880082023 @default.
• W2806488008 crossrefType "journal-article" @default.
• W2806488008 hasAuthorship W2806488008A5006513938 @default.
• W2806488008 hasAuthorship W2806488008A5006997286 @default.
• W2806488008 hasAuthorship W2806488008A5007098026 @default.
• W2806488008 hasAuthorship W2806488008A5009133924 @default.
• W2806488008 hasAuthorship W2806488008A5009282279 @default.
• W2806488008 hasAuthorship W2806488008A5011213325 @default.
• W2806488008 hasAuthorship W2806488008A5011728381 @default.
• W2806488008 hasAuthorship W2806488008A5011893848 @default.
• W2806488008 hasAuthorship W2806488008A5014816629 @default.
• W2806488008 hasAuthorship W2806488008A5020724517 @default.
• W2806488008 hasAuthorship W2806488008A5021292901 @default.
• W2806488008 hasAuthorship W2806488008A5022957204 @default.
• W2806488008 hasAuthorship W2806488008A5038662347 @default.
• W2806488008 hasAuthorship W2806488008A5044284630 @default.
• W2806488008 hasAuthorship W2806488008A5047268222 @default.
• W2806488008 hasAuthorship W2806488008A5054006135 @default.
• W2806488008 hasAuthorship W2806488008A5061783443 @default.
• W2806488008 hasAuthorship W2806488008A5064342215 @default.
• W2806488008 hasAuthorship W2806488008A5081885557 @default.
• W2806488008 hasAuthorship W2806488008A5082292870 @default.
• W2806488008 hasBestOaLocation W28064880081 @default.
• W2806488008 hasConcept C118487528 @default.
• W2806488008 hasConcept C118552586 @default.
• W2806488008 hasConcept C141071460 @default.
• W2806488008 hasConcept C142724271 @default.
• W2806488008 hasConcept C168563851 @default.
• W2806488008 hasConcept C203092338 @default.
• W2806488008 hasConcept C204787440 @default.
• W2806488008 hasConcept C27081682 @default.
• W2806488008 hasConcept C2776572573 @default.
• W2806488008 hasConcept C2778233873 @default.
• W2806488008 hasConcept C2778257484 @default.

• next